Nastizol

Quick links to important sections

Nastizol

Method of action: Antitussive, Antitussive Opioid

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nastizol

Quick Facts

Property Description
Active Ingredients Chlorpheniramine and Pseudoephedrine
Form Fixed-dose combination (Tablet, Capsule, Liquid, Syrup, Oral drops)
Pharmacological Class Antihistamine/Decongestant Combination
Common Use Relief of upper respiratory symptoms
Origin Synthetic

Nastizol: An Upper Respiratory Fixed-Dose Combination

Nastizol is a pharmaceutical preparation classified as a fixed-dose combination drug, designed for oral administration to address symptoms in the upper respiratory tract. This drug is synthetic in origin and is categorized as an Upper Respiratory Combination. This approach allows a single form—such as a tablet, capsule, syrup, or oral drops—to deliver two distinct therapeutic actions simultaneously for managing multiple concurrent symptoms. Nastizol is often positioned for use in adults and older children, addressing the typical presentation of nasal and sinus congestion.

Composition and Pharmacological Class (Chlorpheniramine and Pseudoephedrine)

The core composition of Nastizol is defined by its two active ingredients: Chlorpheniramine and Pseudoephedrine. These ingredients belong to complementary pharmacological classes. Chlorpheniramine is a first-generation antihistamine, while Pseudoephedrine is categorized as a sympathomimetic agent and a nasal decongestant. The combined nature means the product falls under the category of an Antihistamine/Decongestant combination. This combination of agents is intended for integrated relief from allergic rhinitis symptoms.

General Purpose: Why is this Dual Action Necessary?

The general purpose of Nastizol is to provide integrated relief from the discomfort caused by both allergic reactions and congestion associated with colds or allergies. The dual composition is intentional: the antihistamine works to mitigate allergy-related signals like sneezing and a runny nose, while the decongestant causes vasoconstriction—or the narrowing of small blood vessels—in the nasal lining. This combined action helps to reduce tissue swelling and nasal blockage, promoting overall comfort and improved nasal airflow.

Regulatory References

  1. Chlorpheniramine/Pseudoephedrine Drug Label (NIH/DailyMed)
  2. Pharmacology of alpha-adrenergic decongestants - PubMed

What side effects are possible with Nastizol?

Possible Side Effects and Safety Information

Adverse reactions to Nastizol (Chlorpheniramine and Pseudoephedrine) are officially documented and classified by frequency and the body system affected. The drug's safety profile is defined by effects related to its two active components, primarily impacting the central nervous system and the cardiovascular system.


Frequency-Classified Adverse Reactions

The most commonly listed effects in regulatory documentation are often associated with the antihistamine component:

  • Very Common: Drowsiness and Sedation, Dry mouth.
  • Common: Nervousness, Insomnia, Dizziness, and Headache. These effects are often associated with the decongestant component.
  • Rare/Frequency Not Known: Serious adverse events are rare but include severe cutaneous adverse reactions (SCARs), blood disorders such as agranulocytosis, and neurovascular events like ischemic colitis or stroke. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.

System-Organ Classes and Safety Considerations

Official labeling groups effects across several systems, including Nervous System Disorders, Cardiac Disorders (e.g., tachycardia, palpitations), and Psychiatric Disorders (e.g., restlessness, anxiety).

The safety profile includes specific constraints for particular groups. Older adults may have an increased risk of anticholinergic effects like confusion and urinary retention. In the pediatric population, there is potential for paradoxical CNS stimulation, leading to excitability instead of sedation.

Furthermore, regulatory documents specify use is constrained by pre-existing conditions. Nastizol is formally restricted or contraindicated in individuals with severe or uncontrolled hypertension or those taking Monoamine Oxidase Inhibitors (MAOIs), due to the risk of hypertensive crisis. The label notes that the medication may also impair the physical abilities required for driving or operating machinery.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose from Nastizol (Chlorpheniramine and Pseudoephedrine) as presenting with a range of documented signs from its two active ingredients. Manifestations may include symptoms of central nervous system toxicity, such as severe sleepiness, confusion, tremor, and restlessness. Cardiovascular signs, specifically tachycardia (fast, irregular heartbeat) and hypertension (high blood pressure), are also formally documented.

Required Emergency Actions

Regulatory authorities mandate that any suspected overdose requires immediately seeking emergency medical attention or contacting a Poison Control Center. Life-threatening outcomes, including seizures, coma, and cardiovascular collapse, are documented severe risks. Emergency services must be contacted if the individual has collapsed, has trouble breathing, or cannot be awakened.

Clinical Management and Monitoring

Treatment is officially defined as symptomatic and supportive care. Regulatory guidance indicates that no specific antidote is known for this combination. In a hospital setting, procedural steps may include the use of activated charcoal and instituting cardiac monitoring to manage potential adverse cardiovascular events. Overdose in children is noted to sometimes present with distinct signs, including excitability and hallucinations.

Therapeutic Uses of Nastizol

Nastizol is used to relieve symptoms commonly linked to the flu, the common cold, and allergies. Its main purpose is to support symptom relief, which may help enhance patient comfort while the underlying condition progresses.

Common Clinical Scenarios and Indications

The medicine provides temporary relief for symptoms such as fever, minor aches and pains, headache, nasal congestion, and a runny nose. This makes it a helpful choice when a patient experiences these concurrent discomforts. This type of product is used for the temporary relief of common cold and flu symptoms.

Patient Benefit

The key role of this product is the temporary alleviation of multiple symptoms, which may assist with daily activities and patient comfort.

Quick Facts

Quick Fact: Relief for Multiple Cold and Flu Symptoms

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Nastizol eligibility is strictly defined by governmental regulatory labeling for its active components, Chlorpheniramine and Pseudoephedrine. Use is approved for Adults and Adolescents 12 years and older.

Absolute Prohibitions

The medicine is contraindicated in patients with:

  • Severe Hypertension or Severe Coronary Artery Disease (CAD).
  • Concurrent use of, or within 14 days of stopping, Monoamine Oxidase Inhibitor (MAOI) therapy.
  • Narrow-Angle Glaucoma, Urinary Retention, or specific gastrointestinal obstructions.
  • Newborn and premature infants.

Restricted Populations

  • Age-Based Restrictions: Use is generally not recommended in children under 12 years. Regulatory guidance also advises against use in children under 4 years of age. Older adults (65 years and older) require caution.
  • Physiological State: Use during Lactation (breastfeeding) is generally contraindicated. Pregnant individuals must consult a health professional before use.
  • Comorbidity Caution: Caution is required for patients with Severe Hepatic or Severe Renal Impairment, Diabetes, Hyperthyroidism, or specific breathing problems like chronic bronchitis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Nastizol (Chlorpheniramine/Pseudoephedrine) is defined by documented pharmacodynamic and pharmacokinetic interaction patterns, leading to several mandatory restrictions.

Contraindicated and Restricted Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a contraindicated combination as stated in regulatory labeling. This is due to the risk of severe hypertensive crisis and exaggerated anticholinergic effects. Administration of Nastizol is prohibited until at least 14 days after therapy with an MAOI has been discontinued. The combination with other Sympathomimetic Agents (e.g., other decongestants) is also restricted due to the risk of additive cardiovascular effects.

Pharmacodynamic and Exposure Interactions

Interactions involving additive central nervous system (CNS) depression are officially documented when Nastizol is taken with alcohol or other CNS Depressants, such as opioids, sedatives, or tranquilizers. Furthermore, the official profile notes exposure-altering interactions: Alkalinizing Agents (e.g., Acetazolamide) may increase the serum concentration of Pseudoephedrine by reducing its clearance through altered renal excretion. Conversely, Acidifying Agents may reduce its serum concentration. This structure highlights the critical timing-based rule and the formal classification of additive effects present in government drug labels.

Mechanism of Action

How Nastizol Works

The pharmacological action of Nastizol is determined by two complementary mechanistic domains that influence chemical signaling and local vascular response.


Modulating the Histaminergic Pathway via H1 Inverse Agonism

This core mechanism involves the action of Chlorpheniramine as an inverse agonist at the Histamine H1 receptors. This interaction stabilizes the receptor's inactive state, and decreases the signaling cascade normally initiated by histamine. This molecular suppression of the inflammatory mediator decreases capillary permeability and subsequent fluid extravasation, reducing tissue edema and glandular output.


Adrenergic Control of Nasal Vascular Tone

This domain is governed by Pseudoephedrine, which exerts a sympathomimetic action primarily through Alpha1 (alpha1) adrenergic receptor signaling. By promoting the release of norepinephrine and acting as a weak direct agonist, the drug causes vasoconstriction of the arterioles within the nasal mucosa. This physiological adjustment reduces localized blood flow and tissue volume, causing tissue detumescence (shrinkage).

Dosage and Administration Information

How to Use Nastizol

Nastizol is a fixed-dose combination product containing Chlorpheniramine and Pseudoephedrine, and its usage is guided by administration patterns for temporary symptom relief. The medication is only administered via the oral route.


Official Administration Guidelines

Category Instruction Principle
Route of Administration Oral Use Only
Dosing Frequency As-needed (PRN) basis. Immediate-release forms require dosing every 4 to 6 hours.
Maximum Dosing Intake must not exceed 4 doses in any 24-hour period for immediate-release preparations.
Course Duration Use is limited to temporary relief and should typically not exceed 7 days.

Administration and Population Considerations

The standard adult dose (age 12 and older) for the immediate-release tablet is 4 mg of Chlorpheniramine and 60 mg of Pseudoephedrine per single unit. This medication may be taken with or without food.

Special Handling: Extended-release dosage forms must be swallowed whole and should not be crushed, broken, or chewed. Liquid or syrup formulations must be accurately measured using a calibrated measuring device to ensure dose precision.

Population-Specific Rules: Dosing considerations apply to older adults (65 and over), for whom a smaller dose may be necessary. The product is not generally recommended for use in children under 6 years and requires professional guidance for pediatric populations.

Recent Clinical Evidence

Evidence for Use in Common Cold Symptoms

The research was studied for conditions where symptoms may vary in intensity, such as the common cold, and has primarily involved short-term, randomized controlled trials (RCTs) and meta-analyses. This research was applied in studies examining patient-reported experiences related to outcomes linked to inflammatory or irritative states. Researchers explored outcomes related to physical discomfort by measuring changes in patient-reported outcomes describing perceived discomfort and objective nasal airflow measures. Study populations included generally healthy Adults and Older Children (e.g., ages 6 through 11 years). Findings describe patterns observed in the studies over short observation periods, often focusing on the first 3 to 5 days of the cold.

Evidence for Use in Allergic Rhinitis

The use of this drug combination was evaluated in research exploring short-term symptom changes, specifically for seasonal allergic rhinitis. Research examined outcomes capturing phases of heightened symptom activity, such as sneezing and nasal discharge. The research often involved intermediate-term, double-blind RCTs that included Adults and Adolescents (e.g., 12 years and older) experiencing allergic symptoms. Studies tracked patient-reported outcomes describing perceived discomfort over defined time intervals, sometimes up to two weeks. Findings help contextualize how patients reported their experience compared to comparison treatments.

Duration of Evidence and Follow-up in Studies

Research exploring short-term symptom changes typically observed responses over defined time intervals ranging from a few hours after a single dose to the 3 to 5-day duration of an acute cold. Evidence for allergic rhinitis often extends to an intermediate-term follow-up of up to 14 days. These follow-up durations were limited and only provide insight into acute or short-term changes. There is limited information for long-term outcomes regarding the repeated or prolonged use of this combination.

What is Still Uncertain About the Research Base

The research base has several acknowledged limitations. Comparative evidence is lacking for trials that directly test the fixed-dose combination against its individual components administered at the same time. Furthermore, data for certain groups remain insufficient, particularly for young children (under 6 years of age). Subgroup findings are uncertain for certain populations, and evidence quality varies across studies, suggesting that research provides context but not individual predictions. The study results reflect the specific conditions under which they were conducted.

Key Studies & References ALLERGY RELIEF D - chlorpheniramine maleate, pseudoephedrine hcl tablet (FDA/DailyMed Label)

Frequently Asked Questions (FAQ)

Common questions about Nastizol (FAQ)


Q: How quickly does Nastizol usually start to work?

Official product information suggests that the decongestant component, Pseudoephedrine, begins to relieve nasal congestion soon after intake. This onset of action is generally observed within 30 minutes to one hour after administration.


Q: What kind of common pain relievers might interact with Nastizol?

Regulatory information cautions against combining the decongestant component of Nastizol with other cold or pain medications because they might contain similar active ingredients. Taking them together could lead to excessive intake of ingredients like other decongestants. Patients are generally advised to carefully check the labels of all over-the-counter products.


Q: What happens if a person misses a dose of Nastizol?

Regulatory patient information states that a dose can be taken when needed if one is missed. It is required to not take a double dose to compensate. A person must always leave the recommended minimum time interval between doses (such as the 4 hours for immediate-release forms).


Q: Is Nastizol safe for people with certain heart conditions?

Official regulatory documents indicate that Nastizol is contraindicated (should not be used) in patients with severe or uncontrolled hypertension (high blood pressure) and severe coronary artery disease. Caution is also advised for use in people with other types of underlying cardiovascular disorders.


Q: Can Nastizol be used by the elderly?

Regulatory safety information notes that use in older adults (age 65 and older) is associated with an increased risk of specific adverse effects, such as confusion, dizziness, and urinary retention. Regulatory guidance indicates a smaller dose may be considered for this population.


Q: What does the research say about Nastizol's effectiveness?

Research has described that the combination of ingredients provides a short-term change in the severity of overall cold and allergy symptoms in adults. The combination is recognized for its function in managing multiple concurrent upper respiratory symptoms.


Q: Is Nastizol generally safe to use while breastfeeding?

Official guidance states that this combination is generally contraindicated while breastfeeding. Regulatory safety data indicates the active components pass into breast milk and may potentially cause side effects, such as irritability or sedation, in the infant, and may also affect milk supply.


Q: What if a person takes more Nastizol than officially recommended?

Taking more than the recommended amount is hazardous and is defined in regulatory documents as an overdose. Potential serious side effects include a fast or irregular heartbeat, restlessness, and vomiting. Official documentation advises contacting poison control or emergency services if an overdose occurs.


Q: What age group is Nastizol primarily studied for?

Clinical trials for Nastizol are primarily focused on Adults and Adolescents 12 years and older. Official indications and clinical trials primarily focus on Adults and Adolescents 12 years and older.


Q: Can Nastizol be taken at the start of a cold?

Nastizol is officially indicated for the temporary relief of symptoms associated with the common cold or upper respiratory allergies. This means it can be used to manage symptoms that may be present at the start of a cold, such as sneezing, runny nose, and congestion.


Q: What is the typical length of time a person might take Nastizol?

Official regulatory labeling specifies that the use of Nastizol is intended for temporary symptom relief and should typically not exceed 7 days.


Q: Is Nastizol known to interact with caffeine?

The decongestant component of Nastizol is classified as a sympathomimetic agent (a stimulant). Regulatory warnings for this class of drugs advise caution because taking them with other stimulants, including caffeine, may potentially increase the risk of cardiovascular side effects like higher blood pressure or an increased heart rate.


Q: Why is Nastizol sometimes used in combination with other medicines?

Nastizol itself is a fixed-dose combination of an antihistamine and a decongestant. The product is used because this specific combination effectively treats a range of cold and allergy symptoms simultaneously, addressing both allergic signaling and nasal congestion.


Q: Does Nastizol only treat symptoms, or does it also help recovery?

Official information defines this medication as a symptomatic treatment only. It is defined as a symptomatic treatment, meaning it helps manage discomfort but is not intended to alter the underlying cause or duration of the illness.


Q: Why does Nastizol need to be taken a certain number of times per day?

The required frequency of dosing, such as every four to six hours, is determined by the duration of action of the active ingredients within the body. This schedule is necessary to ensure continuous temporary symptom relief.


Q: Can Nastizol cause stomach upset or nausea?

Yes, official regulatory documents list both nausea and upset stomach among the potential side effects that may occur. Nausea and upset stomach are listed among potential side effects. Users are encouraged to reference the full safety documentation.


Q: Does Nastizol interact with herbal supplements?

Regulatory sources advise caution when taking Nastizol with herbal remedies or supplements because there is often limited information about specific drug interactions. Official patient counseling materials often advise patients to inform healthcare professionals about all products they use, including supplements.


Q: What are the official guidelines regarding Nastizol and pregnancy?

Official safety guidelines state that the safety of this combination has not been conclusively established during pregnancy. Regulatory labeling advises that use should be avoided during the first trimester, and consulting a healthcare professional is advised before use at any time during pregnancy.


Q: Is Nastizol a non-sedating medication?

No. The antihistamine component in Nastizol is classified as a first-generation antihistamine, which is a sedating antihistamine. Regulatory documentation lists drowsiness and sedation as very common side effects associated with the product.


Q: What is the difference between Nastizol and an antihistamine alone?

Nastizol contains two active components: an antihistamine (Chlorpheniramine) to manage symptoms like sneezing and runny nose, and a decongestant (Pseudoephedrine) to reduce nasal congestion (stuffy nose). An antihistamine alone typically lacks the ingredient necessary for reducing nasal swelling via vasoconstriction.


Q: Can Nastizol be used for sinus headaches?

Nastizol is officially indicated for the temporary relief of symptoms associated with upper respiratory allergies and the common cold. These indications include symptoms linked to nasal congestion and sinus pressure, which may contribute to what a person experiences as a sinus headache.


Q: Is it possible to have an allergic reaction to Nastizol itself?

Although rare, it is possible to have an allergic reaction to any drug, including Nastizol or its ingredients. Official warnings advise against use if a person has a known allergy to any of the product’s components.


Q: Why are people often told to limit use of Nastizol?

Use is generally limited to a maximum of seven days because prolonged or excessive use of the decongestant component can lead to rebound congestion (worsening congestion once the drug is stopped) and an increased risk of specific cardiovascular side effects.


Q: Does Nastizol contain any stimulants?

Yes. The decongestant component, Pseudoephedrine, is pharmacologically classified as a sympathomimetic agent. This agent works by stimulating the nervous system and is associated with effects like nervousness, insomnia, and restlessness.


Q: Are there different strengths or formulations of Nastizol?

Yes, regulatory documents confirm that Nastizol is available in multiple formulations. These include both immediate-release and extended-release tablets or capsules, as well as oral liquid or syrup forms, which have varying amounts of the active ingredients.


Q: What is the purpose of the ingredients in Nastizol working together?

The ingredients work together to provide integrated relief from multiple concurrent symptoms. The antihistamine addresses allergy signals and runny nose, while the decongestant targets nasal swelling and congestion, thereby maximizing symptomatic relief.


Q: How does Nastizol affect the nasal passages?

The decongestant component, Pseudoephedrine, affects the nasal passages by causing vasoconstriction—the narrowing of small blood vessels in the nasal lining. This action reduces localized blood flow and tissue volume, which helps to shrink the swollen nasal tissues and relieve congestion.


Q: What are the common reasons doctors prescribe Nastizol?

According to official indications, Nastizol is recommended for the temporary relief of symptoms associated with seasonal allergic rhinitis (hay fever), other upper respiratory allergies, and the symptoms of the common cold.


Q: What does official guidance say about discontinuing Nastizol?

For its intended temporary use, official guidance focuses on discontinuing use when symptoms resolve, or when the maximum recommended treatment period (typically 7 days) is reached. There is no complex tapering schedule dictated in the regulatory documentation.


Q: How long does the effect of one dose of Nastizol typically last?

For the immediate-release tablet form, regulatory guidance specifies a dosing frequency of every 4 to 6 hours. This interval is generally used to indicate the typical duration of symptomatic relief provided by a single dose.


How should Nastizol be stored and disposed of?

Nastizol must be stored and handled according to official regulatory specifications to maintain its quality and prevent harm.

Storage Conditions

The medicine is required to be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted between 15 C and 30 C. The product must be kept from freezing and protected from excess heat, light, and moisture. It must be stored in its original container and be tightly closed to preserve its integrity. Child-safety regulations mandate that the medication be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused product should not be flushed down the toilet or poured into a drain. The official preferred method of disposal is to use a drug take-back program. If a take-back option is not available, the medicine should be mixed with an unappealing substance, placed in a sealed plastic bag, and then discarded in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nastizol found in:

A-Z Index: